Cambridge Healthtech Institute’s 6th Annual
Adoptive Cell Therapy – ACT 2
Engineering the Second Generation of CAR Ts, TCRs, and TILs
Part of The Immuno-Oncology Summit
August 5-6, 2019
Efforts to engineer CAR Ts, NKs, TCRs, and TILs with greater precision, safety profiles, and efficacy are leading to the second generation of improved adoptive cell therapies (ACT 2). With multiple engineered receptors already making preclinical impact,
many biotech and pharma companies are preparing for the next wave of clinical trials. The end goal is still the same: improved patient outcomes. However, there remain technical considerations and translational challenges relating to cell therapy development,
manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management. Cambridge Healthtech Institute’s Sixth Annual Adoptive Cell Therapy conference focuses on the next steps needed to deliver CAR, TCR,
and TIL into the clinic.
Cover will include, but is not limited to:
Progress in:
- Chimeric antigen receptors (CAR) including gene edited CAR Ts
- Tandem CARs
- T cell receptors (TCRs)
- Tumor infiltrating lymphocytes (TILs)
- Cytotoxic T lymphocytes (CTLs)
- Next-generation CAR Ts
- NK cells
- T Regs
Impact of:
- Genome editing (CRISPR/Cas 9, TAL)
- Gating strategies
- Antigen presentation
- New approaches to activation and engagement
- Kill switches
Potential of:
- Off-the-shelf therapies
- Targeting solid tumors
- Manipulating the tumor microenvironment
- Combination therapies
- New antigens
Solutions for:
- Translation
- Scale-up
- Manufacturing
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is January 11, 2019.
All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
Email: mabrown@cambridgeinnovationinstitute.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com